# Shanghai OPM Biosciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-opm-biosciences-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.opmbiosciences.com
- Total disclosed funding: $44M
- Latest round: Series B (Aug 27, 2020)
- Investors on record: 4

## About

Established in 2013 and based in Shanghai, China, Shanghai OPM Biosciences Co., Ltd. is a biotechnology company that focuses on developing serum-free media for animal cell culture. The firm also provides full solutions for cell culture. OPM has established a 2000 square meter GMP-compliant culture media production workshop, a 1500 square meter culture media research and development laboratory and a 4000 square meter CDMO platform in Zhangjiang Science City. The culture media production line has been certified by ISO9001 and ISO13485.

The business scope of the company include culture medium solution and end-to-end contract development manufacture organization (CDMO). Its OPM® and Sureness® brands provide customers with total technology plus service solutions to accelerate the process of innovative drugs from genetic (DNA) to clinical filing (IND) to clinical sample production. The company has also developed chemically defined media and nutritional additives for a wide range of CHO cells, chemically defined media and nutritional additives for HEK293 cells. OPM has served more than 300 customers, such as Jiangsu Hengrui Medicine Co.,Ltd., Changchun GeneScience Pharmaceutical Co., Ltd., Hengrui Pharmaceutical, and EpimAb.

## Funding rounds

- Series B, Aug 27, 2020, $44M — CPE Funds Management, CoStone Capital, 3E Bioventures Capital
- Series A, Oct 25, 2017 — Fortune Capital

## Investors

- Fortune Capital — Series A
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series B
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B